Category: Pα+ - Page 9 - Psychedelic Alpha

Read more about the article European Medicines Agency CMO Talks Psychedelics and Their Therapeutic Use in Live Q&A

European Medicines Agency CMO Talks Psychedelics and Their Therapeutic Use in Live Q&A

Post published:May 9, 2024
Post category:Analysis News Pα+

Read more about the article FDA Advisory Committee to Review Lykos Therapeutics’ MDMA-Assisted Therapy in Early June

FDA Advisory Committee to Review Lykos Therapeutics’ MDMA-Assisted Therapy in Early June

Post published:May 7, 2024
Post category:Analysis News Pα+

Read more about the article Reunion Neuroscience Gets a New Lease of Life with $103M Series A to Fund Phase 2 Studies of 4-HO-DiPT Prodrug

Reunion Neuroscience Gets a New Lease of Life with $103M Series A to Fund Phase 2 Studies of 4-HO-DiPT Prodrug

Post published:May 3, 2024
Post category:Analysis News Pα+

Read more about the article Pα+ Psychedelic Patent Analysis: March 2024

Pα+ Psychedelic Patent Analysis: March 2024

Post published:April 30, 2024
Post category:Psychedelic Patent Analysis Pα+

Read more about the article Pα+ Psychedelic Bulletin #162: EQUULUS Therapeutics Emerges from Stealth; Responses to ICER’s Draft Evidence Report on Lykos’ MDMA; and more…

Pα+ Psychedelic Bulletin #162: EQUULUS Therapeutics Emerges from Stealth; Responses to ICER’s Draft Evidence Report on Lykos’ MDMA; and more…

Post published:April 25, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article Insights from the European Medicines Agency’s Psychedelics Workshop: A Pα+ Dispatch

Insights from the European Medicines Agency’s Psychedelics Workshop: A Pα+ Dispatch

Post published:April 23, 2024
Post category:Analysis News Pα+

Read more about the article Pα+ Psychedelic Bulletin #161: Numinus Shifts Focus to US; Algernon Makes DMT for Stroke Lead Asset; atai Pivots to IV Ibogaine

Pα+ Psychedelic Bulletin #161: Numinus Shifts Focus to US; Algernon Makes DMT for Stroke Lead Asset; atai Pivots to IV Ibogaine

Post published:April 17, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article Developing Esketamine (Spravato) and Lessons for Psychedelic Drug Developers with Jaskaran Singh

Developing Esketamine (Spravato) and Lessons for Psychedelic Drug Developers with Jaskaran Singh

Post published:April 12, 2024
Post category:Interviews Pα+

Read more about the article MindMed’s ‘Total Elimination’ of Psychotherapy in LSD Study Stokes Debate Around Its Role in Psychedelic Therapies

MindMed’s ‘Total Elimination’ of Psychotherapy in LSD Study Stokes Debate Around Its Role in Psychedelic Therapies

Post published:April 5, 2024
Post category:Analysis Pα+

Read more about the article Pα+ Psychedelic Patent Analysis: February 2024

Pα+ Psychedelic Patent Analysis: February 2024

Post published:March 30, 2024
Post category:Psychedelic Patent Analysis Pα+

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.